Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 566 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vaginal Diseases Clear all

Conditions: Labor, Premature
Interventions: Magnesium, Nifedlipine; Drug
Lead sponsor: MemorialCare; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Carcinoma, Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Metastatic Vaginal Adenocarcinoma, Metastatic Vaginal Carcinoma, Metastatic Vulvar Carcinoma, Recurrent Cervical Adenocarcinoma, Recurrent Cervical Carcinoma, Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Adenocarcinoma, Vulvar Squamous Cell Carcinoma
Interventions: Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Tremelimumab; Biological · Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Stress Urinary Incontinence
Interventions: Tension-free Vaginal Tape, Monarc sub-fascial hammock; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: Baltimore, Maryland • Cincinnati, Ohio • Cleveland, Ohio

Conditions: Endometrial Cancer, Brachytherapy, Quality of Life
Interventions: Tapered applicator, Standard applicator; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cervical Carcinoma, Ovarian Carcinoma, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Supportive Care, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Duarte, California

Conditions: Vaginismus, Dyspareunia
Interventions: Milli Vaginal Dilator; Device
Lead sponsor: Materna Medical; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Vaginosis, Vaginosis, Bacterial, Vaginal Discharge
Interventions: Estrogen vaginal cream, Trimo-San vaginal gel; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 40 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Vaginosis, Bacterial, Premature Birth, Birth Weight, Chorioamnionitis
Interventions: oral versus vaginal metronidazole; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 16 Years and older · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Lake Worth, Florida + 19 more

Conditions: Infertility
Interventions: INVOcell; Device
Lead sponsor: INVO Bioscience, Inc.; Industry
Eligibility: 18 Years to 37 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Greenville, South Carolina • West Columbia, South Carolina • San Antonio, Texas + 1 more

Conditions: Trichomonas Vaginitis
Interventions: Not listed
Lead sponsor: Tulane University Health Sciences Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Vaginosis, Bacterial
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sexual Function
Interventions: Perineorrhaphy; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 19 Years to 105 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Winston-Salem, North Carolina

Conditions: Urinary Incontinence, Stress, Uterine Prolapse, Vaginal Prolapse
Interventions: Burch urethropexy at time of sacrocolpopexy; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 7
States / cities: Birmingham, Alabama • Maywood, Illinois • Iowa City, Iowa + 4 more

Conditions: Oropharyngeal Cancer, Neck Cancer, Human Papillomavirus, HPV, Anal Cancer, Cervical Cancer, Penile Cancer, Vulvar Cancer, Vaginal Cancer, Colon Cancer
Interventions: Bintrafusp Alfa, PDS01ADC, Entinostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2008
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • San Francisco, California

Conditions: Urinary Tract Infections
Interventions: Mona Lisa Touch, Conjugated estrogen, Estradiol; Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cervical Cancer, Endometrial Cancer, Rectal Cancer, Anal Cancer
Interventions: Vaginal Dilator; Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 85 Years · Female only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: HIV Infections
Interventions: Tenofovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 5
States / cities: New York, New York • The Bronx, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Vaginal Infection, Vaginal Discharge, Vaginosis, Sexual Dysfunction
Interventions: LiviWell Postcoital Vaginal Insert; Device
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Mountain Lakes, New Jersey

Conditions: Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions: Replens and coconut oil; Combination Product
Lead sponsor: Alta Bates Summit Medical Center; Other
Eligibility: Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Vaginal Discharge, Dyspareunia, Female Sexual Dysfunction, Vaginitis, Bacterial Vaginoses
Interventions: Tampon-like device for absorption of sexual fluids; Device
Lead sponsor: Atlantic Health System; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Denville, New Jersey

Conditions: Bacterial Vaginosis
Interventions: 750 mg metronidazole/ 200 mg miconazole vaginal suppository, Standard of care; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse, Cystocele, Uterine Prolapse, Vaginal Prolapse, Pelvic Floor Disorders
Interventions: Conjugated Estrogens Cream, Placebo Cream; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 48 Years and older · Female only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Birmingham, Alabama • Providence, Rhode Island • Dallas, Texas

Search by objective public record fields.

Tocolytics Trial: Intravenous (IV) Magnesium Versus Oral Nifedpine in Fetal Fibronectin (FFN) Postive Population

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Study Comparing Tension-free Vaginal Tape With the Monarc Procedure for Stress Urinary Incontinence

A Novel Tapered Applicator for Vaginal Vault Brachytherapy

Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers

Prospective on Market Patient-reported Outcomes for Milli

Postmenopausal Pessary Users: Estrogen Versus Trimosan

Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

Assessment of the INVOcell Intravaginal Culture System

DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women

Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women

Evaluating Sexual Function After Vaginal Repair With Perineorrhaphy

Colpopexy and Urinary Reduction Efforts (CARE) Protocol

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

The Biology of HIV Transmission

Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection

Study of Vaginal Dilator Use After Pelvic Radiotherapy

Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel

Evaluation of a Postcoital Sponge on Self-Reported Vaginal Health Parameters

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

Evaluation of a Novel Female Hygiene Device for Postcoital Discomfort

Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis

Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen